Basic Information

Gene symbol TNFRSF17 Synonyms BCM, BCMA, CD269, TNFRSF13A Type of gene protein-coding
Description TNF receptor superfamily member 17

GTO ID GTC2802
Trial ID NCT05066646
Disease Multiple Myeloma
Altered gene BCMA
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment CT103A
Generation2nd
PhasePhase1|Phase2
Recruitment statusRecruiting
TitleA Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)
Year2021
CountryChina
Company sponsorNanjing IASO Biotherapeutics Co., Ltd
Other ID(s)XL-LCYJ-0007
Vector information
Vectorlentivirus
ConstructscFv-4-1BB-CD3ζ
Transgene/Inserted genefully human scFv; CD8a hinge; transmembrane domain; 4-1BB costimulatory; CD3ζ activation domains

Clinical Result

Cohort 1
Administration route intravenous infusion
Dosage 1E6 cells/kg
Donor type Autologous
Pts 103
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 74/100(CR); 21/100(PR). For 12 subjects who have previously been treated with CAR T-cell therapy, ORR was 75%, with ≥CR rate of 41.7%, VGPR of 8.3%, and PR of 25%.
Adverse reactions 93.2%(CRS)
References DOI: 10.1182/blood-2022-166465

Relationship Graph

Overview of Knowledge Graph